Glycogen phosphorylase BB as a potential marker of cardiac toxicity in patients treated with anthracyclines for acute leukemia

Abstract

We evaluated acute and chronic cardiotoxicity of anthracyclines with plasma glycogen phosphorylase BB (GPBB) measured by ELISA. We found that acute leukemia patients treated with anthracycline-based chemotherapy have significantly higher plasma GPBB concentrations in comparison with healthy subjects and GPBB after treatment correlated with diastolic left ventricular dysfunction on echocardiography.

Keywords

• glycogen phosphorylase BB
• cardiac toxicity
• chemotherapy
• anthracyclines
• acute leukemia